- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Debra Boyer: Despite Setbacks, Some Pediatric Pulmonary Treatments Have Improved
Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee says that even though there are strides to be made in pediatric pulmonology, treatments for children with diseases, such as cystic fibrosis, have improved.
Adults and children with cystic fibrosis have seen treatment improvements, despite treatment limitations for other respiratory diseases, says Debra Boyer, MD, pediatric pulmonologist at Nationwide Children’s Hospital and co-chair of the American Thoracic Society International Conference Committee.
Transcript
How have pulmonology treatments for pediatric patients evolved?
Despite what I've said before about some of the limitations, things have evolved tremendously. I think cystic fibrosis (CF) is a prime example. I think all of the work that's been done on the CF modulator therapies; you can't even quantify certainly the emotions that have gone into this, but kids are doing so much better, and adults are now doing so much better with cystic fibrosis because of those early interventions. Similarly, maybe not as giant steps in things like asthma and some of the other conditions that we treat, you've seen some improvements in those as well. But cystic fibrosis is by far the one with the biggest steps that we've seen.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
